摘要
目的:探讨匹多莫德治疗在预防老年慢性阻塞性肺疾病(COPD)患者感染性疾病发生中的应用及其安全性。方法:选取2012年12月-2015年12月本院确诊治疗的老年COPD患者100例,按照随机数字表法分为观察组和对照组,每组50例,对照组患者给予保持呼吸道通畅、吸氧、营养支持、祛痰、解痉等对症治疗,观察组患者在此基础上给予800 mg匹多莫德口服治疗,随访12个月,统计分析所有患者治疗前后血清超敏C反应蛋白(hs-CRP)、白细胞计数(WBC)、中性粒细胞计数(NEUT)水平、感染性疾病和不良反应发生情况。结果:观察组患者治疗后血清hs-CRP、WBC、NEUT水平均低于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05);观察组患者治疗后6、12个月的感染性疾病发生率均低于对照组,差异均有统计学意义(P<0.05)。结论:匹多莫德治疗可有效改善老年COPD患者的炎症状态,有利于预防患者感染性疾病的发生,且具有良好的安全性,值得临床进一步推广。
Objective： To discuss the application and safety of Pidotimod therapy for preventing infectious disease of elderly patients with COPD.nethod： From December 2012 to December 2015, 100 elderly patients with COPD treated in our hospital were selected and divided into the observation group and the control group according to the random number table method, 50 cases in each group.The control group was given regular symptomatic treatment such as keep respiratory tract unobstructed, oxygen uptake, nutrition support, expectorant, spasmolysis, the observation group was given 800 mg Pidotimod on the basis of the control group, both of two groups followed up for 12 months, senlm hypersensitive C-reactive protein （ hs-CRP ） and white blood cell count （ WBC ）, neutrophil counts （ NEUT ） levels, infectious diseases and adverse reactions occurrence condition of two groups before and after treatment were statistical analyzed.Result： The serum hs-CRP, WBC, NEUT levels of the observation group group after treatment were lower than those of the control group, the difference were statistically significant （ P〈0.05 ） .There were no statistically significant difference between two groups＇ adverse reaction rates （ P〉O.05 ） .The infectious disease rates after 6 and 12 months treatment of the observation group were lower than those of the control group, the difference was statistically significant （ P〈0.05 ） .Conclusion： Pidotimod treatment can improve inflammation state of elderly patients with COPD, it is conducive to prevent infectious diseases of elderly patients with COPD, which has ~ood security and worth of further clinical promotion.
出处
《中国医学创新》
CAS
2017年第26期119-123,共5页
Medical Innovation of China
关键词
匹多莫德
老年
慢性阻塞性肺疾病
感染性疾病
安全性
Pidotimod
Elderly
Chronic obstructive pulmonary disease
Infectious disease
safety
